Loading stock data…
Illumina (ILMN)
$176.55-1.10 (-0.62%)
Market ClosedLast close Jun 26
Illumina, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Illumina, Inc. in the Healthcare sector is trading at $176.55 with a market capitalization of $24.8B. Wall Street consensus targets $151.68 (19 analysts), implying a -14.1% move over the next 12 months. The stock is currently near its 52-week high of $182.84, remaining 37.4% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -14.1% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.09B↓ | $1.16B↑ | $1.08B↑ | $1.06B↑ | $1.04B |
| Gross Profit | $721.00M↓ | $759.00M↑ | $733.00M↑ | $695.00M↑ | $683.00M |
| Operating Income | $209.00M↓ | $211.00M↓ | $227.00M↑ | $214.00M↑ | $164.00M |
| Net Income | $134.00M↓ | $334.00M↑ | $150.00M↓ | $235.00M↑ | $131.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$24.83B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
31.88%
Volume
Today's trading volume
2.20M
Recent News
Why Illumina (ILMN) Stock Is Trading Up Today
Shares of genomics company Illumina (NASDAQ:ILMN) jumped 6.6% in the morning session after it appointed a high-profile Eli Lilly executive to its board and a price target increase from Barclays.
Illumina (ILMN) Stock After 80% One-Year Rebound Is The Price Now Justified
How Illumina's Recent Moves Frame the Valuation Question Before getting into detailed valuation models, it helps to step back and ask a simple question: based on what you can see today, does Illumina stock look fairly priced, stretched, or potentially mispriced? Illumina recently closed at US$164.93, with returns of 0.4% over the past week, 14.2% over the past month, 22.8% year to date, and 80.2% over the past year, while returns over the last 3 and 5 years show declines of 7.5% and 64.6%...
Adding Eli Lilly’s R&D Chief to the Board Might Change The Case For Investing In Illumina (ILMN)
Illumina, Inc. recently expanded its Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, as an independent director effective June 16, 2026. His background in drug discovery, clinical development, and precision medicine across cardiometabolic, immunology, and neuroscience fields aligns closely with Illumina’s push into clinical genomics and multiomics. We’ll now examine...
1 Unpopular Stock That Deserves Some Love and 2 Facing Challenges
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Stocks Settle Sharply Lower on Escalating Middle East Tensions
The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.98%. June E-mini S&P futures (ESM26 ) fell -1.62%, and June E-mini Nasdaq futures...